These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15992462)

  • 41. Experience with an assay for prostate-specific antigen and transrectal ultrasonography in the diagnosis of prostate cancer.
    Heman-Ackah CA; Festenstein JB; Hibbert P; Harvey DJ; Bunce CJ; Gelister JS
    Br J Urol; 1997 Mar; 79(3):439-44. PubMed ID: 9117228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early diagnosis of prostate cancer in the Western Cape.
    Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
    S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate biopsy in subjects with abnormal transrectal ultrasonography but normal digital examination findings and prostate-specific antigen levels.
    Shim HB; Lee SE; Park HK; Ku JH
    Int Urol Nephrol; 2007; 39(4):1115-20. PubMed ID: 17610039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels.
    Schmid HP; Ravery V; Billebaud T; Toublanc M; Boccon-Gibod LA; Hermieu JF; Delmas V; Boccon-Gibod L
    Urology; 1996 May; 47(5):699-703. PubMed ID: 8650868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.
    Chiu PK; Roobol MJ; Teoh JY; Lee WM; Yip SY; Hou SM; Bangma CH; Ng CF
    Int Urol Nephrol; 2016 Oct; 48(10):1631-7. PubMed ID: 27349564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.
    Al-Azab R; Toi A; Lockwood G; Kulkarni GS; Fleshner N
    Urology; 2007 Jan; 69(1):103-7. PubMed ID: 17270628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. May ultrasound probe size influence pain perception of needle piercing during transrectal prostate biopsy? A prospective evaluation.
    Fabiani A; Servi L; Filosa A; Fioretti F; Maurelli V; Tombolini F; Tallè M; Mammana G
    Arch Ital Urol Androl; 2016 Oct; 88(3):223-227. PubMed ID: 27711100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective.
    Kash DP; Lal M; Hashmi AH; Mubarak M
    Asian Pac J Cancer Prev; 2014; 15(7):3087-91. PubMed ID: 24815452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of methods of detection for prostate neoplasm].
    Zhong C; Chen M; Wan B
    Zhonghua Zhong Liu Za Zhi; 2001 Jan; 23(1):64-6. PubMed ID: 11783074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy?
    Alivizatos G; Deliveliotis C; Mitropoulos D; Raptides G; Louras G; Karayiannis A; Becopoulos T; Dimopoulos AM
    Urology; 1996 Dec; 48(6A Suppl):71-5. PubMed ID: 8973704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
    el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
    Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol.
    Nicolaiew N; Ploussard G; Chun FK; Xylinas E; Allory Y; Salomon L; de la Taille A
    Urol Int; 2013; 90(3):306-11. PubMed ID: 23295308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men.
    Mettlin C; Lee F; Drago J; Murphy GP
    Cancer; 1991 Jun; 67(12):2949-58. PubMed ID: 1710531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
    Bare R; Hart L; McCullough DL
    Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.
    Potter SR; Horniger W; Tinzl M; Bartsch G; Partin AW
    Urology; 2001 Jun; 57(6):1100-4. PubMed ID: 11377318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer.
    Stamatiou K; Alevizos A; Karanasiou V; Mariolis A; Mihas C; Papathanasiou M; Bovis K; Sofras F
    Urol Int; 2007; 78(4):313-7. PubMed ID: 17495488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
    Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.